Upload
arthur-dorsey
View
215
Download
0
Tags:
Embed Size (px)
Citation preview
Containment of artemisinin resistance at the Cambodia-Thailand border
Sylvia Meek, Technical Director, Malaria Consortium, CMWG Meeting 8 July 2009
Drug Resistance in Southeast Asia
• Asia fought resistance to one drug after another from 1970s to 90s
• Often first found in the same area on Thailand / Cambodia border
• Moved from cheap and simple to costly and complex treatments
• After years of research and debate most countries now use Artemisinin-based Combination Therapies (ACTs)– Debates on choice of drug overrode efforts to improve
delivery and access– Now these are being addressed– Results look good
• Progress towards elimination could be threatened if resistance to artemisinin derivatives appears
The Greater Mekong Subregion
Artemisinin derivative resistance has been detected in Thailand and
Cambodia• Research over last two years has confirmed
increased time for parasites to be cleared• Biggest problem is knowing how far it has spread• In the meantime we cannot wait so a special
containment programme is underway in the areas where there is evidence
Distribution of confirmed malaria cases in the Greater Mekong Subregion, 2007*
Viet Nam, 14,581
Myanmar, 200,679
Thailand, 33,178
China-Yunnan, 6,085
Cambodia, 42,518
Lao PDR, 19,037
Source: National Malaria Control Programmes & WHO*2006 data for Myanmar
The containment strategy
Remove selection pressure
Reduce and ultimately eliminate falciparum malaria
Three Phases of the Response
Phase 3 - the medium-term strategy
Re-defining the goal – Continue containment of artemisinin resistance– Commence elimination of malaria parasites countrywide
during this time period pre-elimination status for Plasmodium vivax is unlikely to be completed but strategy will begin the process
Expanding activities from current containment zones to other malaria areas of the country
Testing, implementing and scaling up innovative “packages” of activities– Several of these will be piloted and refined during Phase
2 supported by WHO, BMGF, USAID and others, so evidence for key decisions is expected in 2010
ObjectivesObjective 1: To detect all malaria cases
(including among mobile/migrant populations) and ensure effective treatment and Pf gametocyte clearance (through single dose primaquine).
Objective 2: To decrease drug pressure for selection of artemisinin resistant malaria parasites by improving access to appropriate treatment and preventing use of monotherapy and substandard drugs in both public and private sectors
Objectives (2)Objective 3: To prevent transmission of artemisinin
resistant malaria parasites among target populations (including mobile/migrant populations) by mosquito control and personal protection
Objective 4: To support containment of artemisinin resistant parasites through comprehensive behavior change communication (BCC), community mobilization, and advocacy
Objective 5: To provide effective management (including information systems and surveillance) and coordination to enable rapid and high quality implementation of the strategy
Key areas of focus• Mobile and migrant populations
– How to reach, what about new economic migrants?
• Surveillance and information systems• Suppression of using monotherapies
– Private sector issues– Understanding patient behaviour
• Joint action by Thailand and Cambodia• Planning for sustainability
Female migrant workers in Komrieng District, Battambang Province. The plastic sheet at the back is used as shelter for
sleeping at night and for keeping their belongings and in case of rain. (source: Kim Sedara, MC/CDC)
Challenges• Need extraordinary efforts to control malaria even where it is
less common– Link between resource allocation and disease burden is
less clear• There are beneficial side-effects
– improving surveillance – improving private sector strategies– Learning to work with mobile populations– Learning for elimination
• Are we missing the main target?– How to determine routes of spread– How to support malaria control in Myanmar/Burma
Challenges (2)• We cannot be complacent and rely on current tools
lasting for ever– Investment in R&D is essential– How much to invest in protecting drugs versus
deploying them and moving on to next ones• We shall continue to lose good tools if we do not take
systems strengthening and regulation seriously– Re-emphasise quality, delivery, diagnosis
• Deciding when to act then raising support is a challenge– If we saw the same amount of evidence in Nigeria
or Ethiopia, what scale of response could we mount?
Priority Partnership Activities
• Gain consensus on strategy components• Plan for contingencies – response scenarios for
different regions• Communicate issues realistically• Review relevant experiences
• Multidisciplinary task force proposed